These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38450219)

  • 1. Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases.
    Ugurluer G; Schneiders FL; Corradini S; Boldrini L; Kotecha R; Kelly P; Portelance L; Camilleri P; Ben-David MA; Poiset S; Marschner SN; Panza G; Kutuk T; Palacios MA; Castelluccia A; Zoto Mustafayev T; Atalar B; Senan S; Ozyar E
    Clin Transl Radiat Oncol; 2024 May; 46():100756. PubMed ID: 38450219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases.
    Mills M; Kotecha R; Herrera R; Kutuk T; Fahey M; Wuthrick E; Grass GD; Hoffe S; Frakes J; Chuong MD; Rosenberg SA
    Clin Transl Radiat Oncol; 2024 Mar; 45():100719. PubMed ID: 38292332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy of Adrenal Metastases from a Single Institution.
    Hoegen-Saßmannshausen P; Jessen I; Buchele C; Schlüter F; Rippke C; Renkamp CK; Weykamp F; Regnery S; Liermann J; Meixner E; Hoeltgen L; Eichkorn T; König L; Debus J; Klüter S; Hörner-Rieber J
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Radiotherapy for Adrenal Metastases: A Multi-Institutional Review of Patient Characteristics and Outcomes - Turkish Society for Radiation Oncology SBRT Group Study (Trod SBRT 10-004).
    Elmali A; Akkus Yildirim B; Cengiz M; Yuce Sari S; Onal HC; Berber T; Arslantas Erken A; Zoto Mustafayev T; Atalar B; Unal I; Kaydihan N; Oner Dincbas F
    Oncol Res Treat; 2022; 45(12):717-727. PubMed ID: 36116432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study.
    Baydoun A; Chen H; Poon I; Badellino S; Dagan R; Erler D; Foote MC; Louie AV; Redmond KJ; Ricardi U; Sahgal A; Biswas T
    Clin Transl Radiat Oncol; 2022 Mar; 33():159-164. PubMed ID: 35243027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
    Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC
    Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
    Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
    Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
    Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
    BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Clinical Results of MR-Guided Stereotactic Body Radiotherapy of Liver Metastases.
    Weykamp F; Hoegen P; Regnery S; Katsigiannopulos E; Renkamp CK; Lang K; König L; Sandrini E; Meixner E; Rippke C; Buchele C; Liermann J; Debus J; Klüter S; Hörner-Rieber J
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis.
    Yuste C; Passerat V; Calais G; Schipman B; Vaugier L; Paumier A; Huertas A; Hemery CG; Debelleix C; Chamois J; Blanchard N; Septans AL; Pointreau Y
    Clin Transl Radiat Oncol; 2024 Mar; 45():100708. PubMed ID: 38162282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
    Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
    BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases.
    Uder L; Nachbar M; Butzer S; Boldt J; Baumeister S; Bitzer M; Königsrainer A; Seufferlein T; Hoffmann R; Gatidis S; Nikolaou K; Zips D; Thorwarth D; Gani C; Boeke S
    Front Oncol; 2022; 12():1095633. PubMed ID: 36727060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease.
    Reshko LB; Gaskins JT; Silverman CL; Dunlap NE
    Rep Pract Oncol Radiother; 2021; 26(3):325-340. PubMed ID: 34277086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry.
    Mahadevan A; Blanck O; Lanciano R; Peddada A; Sundararaman S; D'Ambrosio D; Sharma S; Perry D; Kolker J; Davis J
    Radiat Oncol; 2018 Feb; 13(1):26. PubMed ID: 29439707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions.
    Sandoval ML; Sim AJ; Bryant JM; Bhandari M; Wuthrick EJ; Perez BA; Dilling TJ; Redler G; Andreozzi J; Nardella L; Feygelman V; Latifi K; Rosenberg SA
    JTO Clin Res Rep; 2023 May; 4(5):100488. PubMed ID: 37159821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.
    Chance WW; Nguyen QN; Mehran R; Welsh JW; Gomez DR; Balter P; Komaki R; Liao Z; Chang JY
    Pract Radiat Oncol; 2017; 7(3):e195-e203. PubMed ID: 27743801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
    Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer.
    Rzazade R; Pham NT; Turna M; Canoglu MD; Kucukmorkoc E; Berberoglu K; Caglar HB
    J Radiosurg SBRT; 2022; 8(4):275-282. PubMed ID: 37416328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.